Video

Dr. Gupta discusses bladder cancer research highlights from ASCO 2021

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, gives an overview of key bladder cancer research from the 2021 American Society of Clinical Oncology annual meeting. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.

Related Videos
Helen L. Bernie, DO, MPH, answers a question during a video interview
Team of surgeons | Image Credit: © shefkate - stock.adobe.com
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
November 14th 2024

TENACIO inflatable penile prosthesis pump fills faster compared with MS pump

Benjamin P. Saylor
"We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump," says Justin Lee, MD.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC
November 7th 2024

Phase 3 ENLIGHTED trial: Padeliporfin VTP shows promise in low-grade UTUC

Hannah Clarke
At the end of the induction phase, 86% of patients had achieved a complete response.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Study to assess performance of CxBladder test in urothelial carcinoma surveillance
November 6th 2024

Study to assess performance of CxBladder test in urothelial carcinoma surveillance

Hannah Clarke
The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.
TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma
October 31st 2024

TYRA-300 shows encouraging safety, efficacy in FGFR3+ metastatic urothelial carcinoma

Hannah Clarke
Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.
© 2024 MJH Life Sciences

All rights reserved.